journal article·2024-07-23Open access

Neuroprotective Benefits of Rosmarinus officinalis and Its Bioactives against Alzheimer’s and Parkinson’s Diseases

Danai Kosmopoulou, Maria-Parthena Lafara, Theodora Adamantidi, Anna Ofrydopoulou, Andreas M. Grabrucker, Alexandros Tsoupras

Applied Sciences· Volume 14· Issue 15

Abstract

Neurodegenerative disorders (NDs) are conditions marked by progressively escalating inflammation that leads to the degeneration of neuronal structure and function. There is an increasing interest in natural compounds, especially those from pharmaceutical plants, with neuroprotective properties as part of potential therapeutic interventions. Thus, the rich bioactive content of the perennial herb rosemary (Rosmarinus officinalis) is thoroughly reviewed in this article, with an emphasis on its pleiotropic pharmacological properties, including its antioxidant, anti-inflammatory, and neuroprotective health-promoting effects. In addition, a comprehensive analysis of the existing scientific literature on the potential use of rosemary and its bioactive constituents in treating neurodegenerative disorders was also conducted. Rosemary and its bioactives’ chemical properties and neuroprotective mechanisms are discussed, focusing on their ability to mitigate oxidative stress, reduce inflammation, and modulate neurotransmitter activity. The role of rosemary in enhancing cognitive function, attenuating neuronal apoptosis, and promoting neurogenesis is outlined. Key bioactive components, such as rosmarinic acid and carnosic acid, are also highlighted for their neuroprotective act. The promising outcomes of the conducted pre-clinical studies or clinical trials confirm the efficacy of rosemary in preventing or alleviating Alzheimer’s and Parkinson’s diseases both in vitro (in cells) and in vivo (in animal models of NDs). From this perspective, the applications of rosemary’s bio-functional compounds and extracts in the food, cosmetics, and pharmaceutical sectors are also presented; in the latter, we discuss their use against neurodegenerative disorders, either alone or as adjuvant therapies. This paper critically evaluates these studies’ methodological approaches and outcomes, providing insights into the current state of the clinical research and identifying potential avenues for future investigation. All findings presented herein contribute to the growing body of literature and support the exploration of natural compounds as promising candidates for novel applications and neuroprotective interventions, paving the way for more applied scientific research.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Medicinal Plants and Bioactive Compounds · Saffron Plant Research Studies · Essential Oils and Antimicrobial Activity

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Hephaestus Laboratory, School of Chemistry, Faculty of Science, Kavala University Campus, Democritus University of Thrace, 65404 Kavala, Greece

Department of Biological Sciences, University of Limerick, V94 T9PX Limerick, Ireland

Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland

Health Research Institute (HRI), University of Limerick, V94 T9PX Limerick, Ireland

References (100+)

Show source-provided references
1. Therapeutic Effects of Rosemary (Rosmarinus officinalis L.) and Its Active Constituents on Nervous System Disorders
2. Gonçalves, S., Mansinhos, I., and Romano, A. (2020). Aromatic Plants: A Source of Compounds with Antioxidant and Neuroprotective Effects. Oxidative Stress and Dietary Antioxidants in Neurological Diseases, Elsevier.10.1016/B978-0-12-817780-8.00011-6 ↗
3. Determination of Antioxidant Enzyme Activity and Phenolic Contents of Some Species of the Asteraceae Family from Medicanal Plants10.1016/j.indcrop.2019.05.042 ↗
4. Rosemary (Rosmarinus Officinalis) as a Functional Ingredient: Recent Scientific Evidence10.1016/j.cofs.2016.12.003 ↗
5. Christopoulou, S.D., Androutsopoulou, C., Hahalis, P., Kotsalou, C., Vantarakis, A., and Lamari, F.N. (2021). Rosemary Extract and Essential Oil as Drink Ingredients: An Evaluation of Their Chemical Composition, Genotoxicity, Antimicrobial, Antiviral, and Antioxidant Properties. Foods, 10.10.3390/foods10123143 ↗
6. Rosmarinus officinalis (Rosemary): A Novel Therapeutic Agent for Antioxidant, Antimicrobial, Anticancer, Antidiabetic, Antidepressant, Neuroprotective, Anti-Inflammatory and Anti-Obesity Treatment
7. Rosemary Species: A Review of Phytochemicals, Bioactivities and Industrial Applications10.1016/j.sajb.2021.09.026 ↗
8. De Oliveira, J.R., Camargo, S.E.A., and De Oliveira, L.D. (2019). Rosmarinus officinalis L. (Rosemary) as Therapeutic and Prophylactic Agent. J. Biomed. Sci., 26.10.1186/s12929-019-0499-8 ↗
9. Neurorescue Effect of Rosmarinic Acid on 6-Hydroxydopamine-Lesioned Nigral Dopamine Neurons in Rat Model of Parkinson’s Disease10.1007/s12031-011-9693-1 ↗
10. Carnosic Acid Protects against 6-Hydroxydopamine-Induced Neurotoxicity in in Vivo and in Vitro Model of Parkinson’s Disease: Involvement of Antioxidative Enzymes Induction10.1016/j.cbi.2014.11.011 ↗
11. Carnosol, a Component of Rosemary (Rosmarinus officinalis L.) Protects Nigral Dopaminergic Neuronal Cells10.1097/01.wnr.0000239951.14954.10 ↗
12. Taram, F., Ignowski, E., Duval, N., and Linseman, D. (2018). Neuroprotection Comparison of Rosmarinic Acid and Carnosic Acid in Primary Cultures of Cerebellar Granule Neurons. Molecules, 23.10.3390/molecules23112956 ↗
13. Rosmarinic Acid Protects Human Dopaminergic Neuronal Cells against Hydrogen Peroxide-Induced Apoptosis10.1016/j.tox.2008.06.010 ↗
14. The Dietary Components Carnosic Acid and Carnosol as Neuroprotective Agents: A Mechanistic View10.1007/s12035-015-9519-1 ↗
15. Carnosic Acid Prevents 6-Hydroxydopamine-Induced Cell Death in SH-SY5Y Cells via Mediation of Glutathione Synthesis10.1021/tx300171u ↗
16. Carnosic Acid Protects SH-SY5Y Cells against 6-Hydroxydopamine-Induced Cell Death through Upregulation of Parkin Pathway10.1016/j.neuropharm.2016.04.017 ↗
17. Protective Effect of Carnosic Acid against Paraquat-Induced Redox Impairment and Mitochondrial Dysfunction in SH-SY5Y Cells: Role for PI3K/Akt/Nrf2 Pathway10.1016/j.tiv.2015.12.005 ↗
18. Dhouibi, N., Manuguerra, S., Arena, R., Messina, C.M., Santulli, A., Kacem, S., Dhaouadi, H., and Mahdhi, A. (2023). Impact of the Extraction Method on the Chemical Composition and Antioxidant Potency of Rosmarinus officinalis L. Extracts. Metabolites, 13.10.3390/metabo13020290 ↗
19. Leri, M., Scuto, M., Ontario, M.L., Calabrese, V., Calabrese, E.J., Bucciantini, M., and Stefani, M. (2020). Healthy Effects of Plant Polyphenols: Molecular Mechanisms. Int. J. Mol. Sci., 21.10.3390/ijms21041250 ↗
20. Research and Application Progress of Radiomics in Neurodegenerative Diseases10.1016/j.metrad.2024.100068 ↗
21. What Causes Neurodegenerative Disease?10.5114/fn.2020.96707 ↗
22. Sasikumar, D.S.N., Thiruselvam, P., Sundararajan, V., Ravindran, R., Gunasekaran, S., Madathil, D., Kaliamurthi, S., Peslherbe, G.H., Selvaraj, G., and Sudhakaran, S.L. (2024). Insights into Dietary Phytochemicals Targeting Parkinson’s Disease Key Genes and Pathways: A Network Pharmacology Approach. Comput. Biol. Med., 172.10.1016/j.compbiomed.2024.108195 ↗
23. The Interplay between Neuroinflammatory Pathways and Parkinson’s Disease10.1016/j.expneurol.2023.114644 ↗
24. Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF10.1155/2015/610813 ↗
25. The Relation of Markers of Inflammation to the Development of Glucose Disorders in the Elderly10.2337/diabetes.50.10.2384 ↗
26. C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus10.1001/jama.286.3.327 ↗
27. Reduced Incidence of AD with NSAID but Not H 2 Receptor Antagonists: The Cache County Study10.1212/WNL.59.6.880 ↗
28. Neuroprotective Role of Withania Somnifera Root Extract in Maneb–Paraquat Induced Mouse Model of Parkinsonism10.1007/s11064-013-1005-4 ↗
29. A Review: Progress and Trend Advantage of Dopamine Electrochemical Sensor10.1016/j.jelechem.2024.118157 ↗
30. (2024, April 17). Parkinson Disease. Available online: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease.
31. Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinson’s Disease
32. The Glutathione System in Parkinson’s Disease and Its Progression10.1016/j.neubiorev.2020.10.004 ↗
33. Mitochondrial Dysfunction and Oxidative Stress in Alzheimer’s Disease, and Parkinson’s Disease, Huntington’s Disease and Amyotrophic Lateral Sclerosis—An Updated Review10.1016/j.mito.2023.05.007 ↗
34. Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson’s Disease10.1016/j.cub.2019.11.079 ↗
35. Premotor, Nonmotor and Motor Symptoms of Parkinson’s Disease: A New Clinical State of the Art10.1016/j.arr.2022.101834 ↗
36. Reducing Depression and Anxiety Symptoms in Patients with Parkinson’s Disease: The Effectiveness of Group Cognitive Behavioral Therapy10.1016/j.parkreldis.2023.105456 ↗
37. The Delivery of Tyrosine Hydroxylase Accelerates the Neurorestoration of Macaca Rhesus Model of Parkinson’s Disease Provided by Neurturin10.1016/j.neulet.2012.06.063 ↗
38. The Neuroprotective Effect of Traditional Chinese Medicinal Plants—A Critical Review10.1016/j.apsb.2023.06.009 ↗
39. Review on the Interactions between Dopamine Metabolites and α-Synuclein in Causing Parkinson’s Disease10.1016/j.neuint.2022.105461 ↗
40. De Oliveira, M.R. (2020). Carnosic Acid and Carnosol: Neuroprotection and the Mitochondria. Oxidative Stress and Dietary Antioxidants in Neurological Diseases, Elsevier.10.1016/B978-0-12-817780-8.00015-3 ↗
41. Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson’s Disease: A Systematic Review10.1093/advances/nmab060 ↗
42. Faridzadeh, A., Salimi, Y., Ghasemirad, H., Kargar, M., Rashtchian, A., Mahmoudvand, G., Karimi, M.A., Zerangian, N., Jahani, N., and Masoudi, A. (2022). Neuroprotective Potential of Aromatic Herbs: Rosemary, Sage, and Lavender. Front. Neurosci., 16.10.3389/fnins.2022.909833 ↗
43. What’s in the Pipeline for the Treatment of Parkinson’s Disease?10.1586/14737175.8.12.1829 ↗
44. Medical, Surgical, and Physical Treatments for Parkinson’s Disease10.1016/S0140-6736(23)01429-0 ↗
45. Effects of Different Levodopa Doses on Blood Pressure in Older Patients with Early and Middle Stages of Parkinson’s Disease10.1016/j.heliyon.2023.e17876 ↗
46. Forecasting Prevalence and Mortality of Alzheimer’s Disease Using the Partitioning Models10.1016/j.exger.2023.112133 ↗
47. Alzheimer’s Disease, a Multifactorial Disorder Seeking Multitherapies10.1016/j.jalz.2010.04.006 ↗
48. Volatile Terpenoids as Potential Drug Leads in Alzheimer’s Disease10.1515/chem-2017-0040 ↗
49. 13 Reasons Why the Brain Is Susceptible to Oxidative Stress10.1016/j.redox.2018.01.008 ↗
50. Deuterated Polyunsaturated Fatty Acids Reduce Brain Lipid Peroxidation and Hippocampal Amyloid β-Peptide Levels, without Discernable Behavioral Effects in an APP/PS1 Mutant Transgenic Mouse Model of Alzheimer’s Disease10.1016/j.neurobiolaging.2018.02.024 ↗
51. Butterfield, D.A., and Mattson, M.P. (2020). Apolipoprotein E and Oxidative Stress in Brain with Relevance to Alzheimer’s Disease. Neurobiol. Dis., 138.10.1016/j.nbd.2020.104795 ↗
52. Impact of apoE Deficiency on Oxidative Insults and Antioxidant Levels in the Brain10.1016/S0169-328X(00)00268-0 ↗
53. Chemistry and Biochemistry of 4-Hydroxynonenal, Malonaldehyde and Related Aldehydes10.1016/0891-5849(91)90192-6 ↗
54. Integration of Transcriptomic and Genomic Data Suggests Candidate Mechanisms for APOE4-Mediated Pathogenic Action in Alzheimer’s Disease10.1038/srep32583 ↗
55. Di Domenico, F., Tramutola, A., Barone, E., Lanzillotta, C., Defever, O., Arena, A., Zuliani, I., Foppoli, C., Iavarone, F., and Vincenzoni, F. (2019). Restoration of Aberrant mTOR Signaling by Intranasal Rapamycin Reduces Oxidative Damage: Focus on HNE-Modified Proteins in a Mouse Model of down Syndrome. Redox Biol., 23.10.1016/j.redox.2019.101162 ↗
56. Lipid- and Receptor-Binding Regions of Apolipoprotein E4 Fragments Act in Concert to Cause Mitochondrial Dysfunction and Neurotoxicity10.1073/pnas.0508254102 ↗
57. Elevated Protein-Bound Levels of the Lipid Peroxidation Product, 4-Hydroxy-2-Nonenal, in Brain from Persons with Mild Cognitive Impairment10.1016/j.neulet.2005.12.017 ↗
58. Activities of Mitochondrial Respiratory Chain Complexes in Platelets of Patients with Alzheimer’s Disease and Depressive Disorder10.1016/j.mito.2019.07.013 ↗
59. Neuroprotective Strategies Involving ROS in Alzheimer Disease10.1016/j.freeradbiomed.2010.11.026 ↗
60. Convergence of Amyloid-β and Tau Pathologies on Mitochondria In Vivo10.1007/s12035-010-8109-5 ↗
61. Amyloid-β and Tau Synergistically Impair the Oxidative Phosphorylation System in Triple Transgenic Alzheimer’s Disease Mice10.1073/pnas.0905529106 ↗
62. Lecanemab in Early Alzheimer’s Disease10.1056/NEJMoa2212948 ↗
63. Alzheimer’s Disease Drug Development Pipeline: 202210.1002/trc2.12295 ↗
64. Shi, M., Chu, F., Zhu, F., and Zhu, J. (2022). Impact of Anti-Amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Front. Aging Neurosci., 14.10.3389/fnagi.2022.870517 ↗
65. Antiparasitic Potential of Asteraceae Plants: A Comprehensive Review on Therapeutic and Mechanistic Aspects for Biocompatible Drug Discovery10.1016/j.phyplu.2022.100377 ↗
66. Antimicrobial Activity in Asterceae: The Selected Genera Characterization and against Multidrug Resistance Bacteria10.1016/j.heliyon.2023.e14985 ↗
67. Zhaogao, L., Yaxuan, W., Mengwei, X., Haiyu, L., Lin, L., and Delin, X. (2023). Molecular Mechanism Overview of Metabolite Biosynthesis in Medicinal Plants. Plant Physiol. Biochem., 204.10.1016/j.plaphy.2023.108125 ↗
68. Beyond Aroma: A Review on Advanced Extraction Processes from Rosemary (Rosmarinus officinalis) and Sage (Salvia Officinalis) to Produce Phenolic Acids and Diterpenes10.1016/j.tifs.2022.07.001 ↗
69. Constituents and Biological Activities of Selected Genera of the Iranian Asteraceae Family10.1016/j.hermed.2020.100405 ↗
70. Gupta, P., Chhikara, N., and Panghal, A. (2023). Herbs of Asteraceae Family: Nutritional Profile, Bioactive Compounds, and Potentials in Therapeutics. Harvesting Food from Weeds, Wiley.10.1002/9781119793007 ↗
71. Hechaichi, F.Z., Bendif, H., Bensouici, C., Alsalamah, S.A., Zaidi, B., Bouhenna, M.M., Souilah, N., Alghonaim, M.I., Benslama, A., and Medjekal, S. (2023). Phytochemicals, Antioxidant and Antimicrobial Potentials and LC-MS Analysis of Centaurea Parviflora Desf. Extracts. Molecules, 28.10.3390/molecules28052263 ↗
72. Pharmacognostical Botany: Classification of Medicinal and Aromatic Plants (MAPs), Botanical Taxonomy, Morphology, and Anatomy of Drug Plants10.1007/978-3-319-63862-1_6 ↗
73. Rosemary Essential Oil: Chemical and Biological Properties, with Emphasis on Its Delivery Systems for Food Preservation10.1016/j.foodcont.2023.110003 ↗
74. Diniz Do Nascimento, L., Moraes, A.A.B.D., Costa, K.S.D., Pereira Galúcio, J.M., Taube, P.S., Costa, C.M.L., Neves Cruz, J., De Aguiar Andrade, E.H., and Faria, L.J.G.D. (2020). Bioactive Natural Compounds and Antioxidant Activity of Essential Oils from Spice Plants: New Findings and Potential Applications. Biomolecules, 10.10.3390/biom10070988 ↗
75. An Overview of Cosmeceutically Relevant Plant Extracts and Strategies for Extraction of Plant-Based Bioactive Compounds10.1016/j.fbp.2018.09.002 ↗
76. Kola, A., Hecel, A., Lamponi, S., and Valensin, D. (2020). Novel Perspective on Alzheimer’s Disease Treatment: Rosmarinic Acid Molecular Interplay with Copper(II) and Amyloid β. Life, 10.10.3390/life10070118 ↗
77. Karagianni, K., Pettas, S., Kanata, E., Lioulia, E., Thune, K., Schmitz, M., Tsamesidis, I., Lymperaki, E., Xanthopoulos, K., and Sklaviadis, T. (2022). Carnosic Acid and Carnosol Display Antioxidant and Anti-Prion Properties in In Vitro and Cell-Free Models of Prion Diseases. Antioxidants, 11.10.3390/antiox11040726 ↗
78. Vieira, C., Rebocho, S., Craveiro, R., Paiva, A., and Duarte, A.R.C. (2022). Selective Extraction and Stabilization of Bioactive Compounds from Rosemary Leaves Using a Biphasic NADES. Front. Chem., 10.10.3389/fchem.2022.954835 ↗
79. Carnosic Acid Attenuates 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells by Inducing Autophagy Through an Enhanced Interaction of Parkin and Beclin110.1007/s12035-016-9873-7 ↗
80. NMR-Based Quantification of Rosmarinic and Carnosic Acids, GC–MS Profile and Bioactivity Relevant to Neurodegenerative Disorders of Rosmarinus officinalis L. Extracts10.1016/j.jff.2013.09.008 ↗
81. Role for the PI3K/Akt/Nrf2 Signaling Pathway in the Protective Effects of Carnosic Acid against Methylglyoxal-Induced Neurotoxicity in SH-SY5Y Neuroblastoma Cells10.1016/j.cbi.2015.11.003 ↗
82. Carnosic Acid Suppresses the Production of Amyloid-β 1–42 by Inducing the Metalloprotease Gene TACE/ADAM17 in SH-SY5Y Human Neuroblastoma Cells10.1016/j.neures.2012.11.007 ↗
83. Carnosic Acid Attenuates Apoptosis Induced by Amyloid-β 1–42 or 1–43 in SH-SY5Y Human Neuroblastoma Cells10.1016/j.neures.2014.12.003 ↗
84. Satoh, T., Trudler, D., Oh, C.-K., and Lipton, S.A. (2022). Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer’s Disease, Parkinson’s Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome. Antioxidants, 11.10.3390/antiox11010124 ↗
85. Therapeutic Advantage of Pro-Electrophilic Drugs to Activate the Nrf2/ARE Pathway in Alzheimer’s Disease Models10.1038/cddis.2016.389 ↗
86. Neuroprotective Effects of Carnosic Acid in an Experimental Model of Alzheimer’s Disease in Rats
87. The Protective Role of Carnosic Acid against Beta-Amyloid Toxicity in Rats10.1155/2013/917082 ↗
88. Rosmarinic Acid Mediated Neuroprotective Effects against H2O2-Induced Neuronal Cell Damage in N2A Cells10.1016/j.lfs.2014.07.010 ↗
89. Selective in Vitro and in Silico Butyrylcholinesterase Inhibitory Activity of Diterpenes and Rosmarinic Acid Isolated from Perovskia atriplicifolia Benth. and Salvia glutinosa L10.1016/j.phytochem.2016.10.012 ↗
90. Inhibitory Effect of Turkish Rosmarinus officinalis L. on Acetylcholinesterase and Butyrylcholinesterase Enzymes10.1016/j.foodchem.2007.11.023 ↗
91. Molecular Docking and Ex Vivo and in Vitro Anticholinesterase Activity Studies of Salvia Sp. and Highlighted Rosmarinic Acid10.3906/sag-1404-42 ↗
92. Anticholinesterase Activity of Selected Phenolic Acids and Flavonoids–Interaction Testing in Model Solutions10.5604/12321966.1185777 ↗
93. Structure–Activity Relations of Rosmarinic Acid Derivatives for the Amyloid β Aggregation Inhibition and Antioxidant Properties10.1016/j.ejmech.2017.07.026 ↗
94. Rosmarinic Acid Prevents Fibrillization and Diminishes Vibrational Modes Associated to β Sheet in Tau Protein Linked to Alzheimer’s Disease10.1080/14756366.2017.1347783 ↗
95. The Spice Sage and Its Active Ingredient Rosmarinic Acid Protect PC12 Cells from Amyloid-β Peptide-Induced Neurotoxicity10.1124/jpet.105.099317 ↗
96. Biochemical and Behavioral Effects of Rosmarinic Acid Treatment in an Animal Model of Parkinson’s Disease Induced by MPTP10.1016/j.bbr.2022.114257 ↗
97. Protective Role of Rosmarinic Acid on Amyloid Beta 42-Induced Echoic Memory Decline: Implication of Oxidative Stress and Cholinergic Impairment10.1016/j.neuint.2018.04.008 ↗
98. Perilla frutescens Var. Japonica and Rosmarinic Acid Improve Amyloid-β 25-35 Induced Impairment of Cognition and Memory Function10.4162/nrp.2016.10.3.274 ↗
99. A Natural Scavenger of Peroxynitrites, Rosmarinic Acid, Protects against Impairment of Memory Induced by Aβ25–3510.1016/j.bbr.2007.03.001 ↗
100. Effects of Rosmarinic Acid on Cognitive and Biochemical Alterations in Ovariectomized Rats Treated with D-Galactose10.5603/fhc.a2015.0034 ↗